Hologic announced that it received FDA clearance for its Aptima SARS-CoV-2 Assay. This approval expands the company's molecular diagnostic testing capabilities for infectious diseases.
The Aptima SARS-CoV-2 Assay is designed to run on Hologic's Panther system, which is known for its automated, high-throughput processing. The system can deliver initial results in under three hours, enhancing laboratory efficiency.
This clearance reinforces the versatility and continued relevance of the Panther platform, allowing Hologic to offer a broader menu of tests and support public health needs related to respiratory pathogens.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.